ATE95065T1 - Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten. - Google Patents

Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.

Info

Publication number
ATE95065T1
ATE95065T1 AT88303198T AT88303198T ATE95065T1 AT E95065 T1 ATE95065 T1 AT E95065T1 AT 88303198 T AT88303198 T AT 88303198T AT 88303198 T AT88303198 T AT 88303198T AT E95065 T1 ATE95065 T1 AT E95065T1
Authority
AT
Austria
Prior art keywords
autoimmune disease
susceptibility
allele
antigen
antigens
Prior art date
Application number
AT88303198T
Other languages
English (en)
Inventor
John Todd
John I Bell
Hans Acha-Orbea
Hugh O Mcdevitt
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE95065T1 publication Critical patent/ATE95065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT88303198T 1987-04-09 1988-04-11 Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten. ATE95065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3637287A 1987-04-09 1987-04-09
EP88303198A EP0286447B1 (de) 1987-04-09 1988-04-11 Methode und Mittel zur vorbeugenden Behandlung von Autoimmunkrankheiten

Publications (1)

Publication Number Publication Date
ATE95065T1 true ATE95065T1 (de) 1993-10-15

Family

ID=21888256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303198T ATE95065T1 (de) 1987-04-09 1988-04-11 Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.

Country Status (5)

Country Link
EP (1) EP0286447B1 (de)
JP (1) JPS6434924A (de)
AT (1) ATE95065T1 (de)
CA (1) CA1327162C (de)
DE (1) DE3884440T2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
IL89431A0 (en) * 1989-02-27 1989-09-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
EP0474764A4 (en) * 1989-05-31 1992-11-19 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
JPH08509204A (ja) * 1992-12-17 1996-10-01 スリラム，サブラマニアム 自己免疫疾患の治療のためのｍｈｃクラス▲ｉｉ▼分子のペプチドを用いた予防接種
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
JP2000509022A (ja) * 1996-04-03 2000-07-18 アナージェン，インコーポレイテッド 糖尿病の処置および予防のための環状ペプチドワクチン
WO2001074375A1 (en) * 2000-04-04 2001-10-11 Corixa Corporation Composition for treatment of autoimmune disease
CN102764425B (zh) 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
WO2005036443A1 (ja) * 2003-10-15 2005-04-21 Signpost Corporation 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes

Also Published As

Publication number Publication date
EP0286447B1 (de) 1993-09-29
CA1327162C (en) 1994-02-22
DE3884440T2 (de) 1994-04-28
EP0286447A2 (de) 1988-10-12
JPS6434924A (en) 1989-02-06
DE3884440D1 (de) 1993-11-04
EP0286447A3 (en) 1989-09-27

Similar Documents

Publication Publication Date Title
RU2138512C1 (ru) Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
Deng et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease.
ES2278463T3 (es) Metodo para reducir la inmunogenicidad de proteinas.
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
Gasser et al. Genetic control of susceptibility to experimental allergic encephalomyelitis and the Ag-B locus of rats
ATE95065T1 (de) Methode und mittel zur vorbeugenden behandlung von autoimmunkrankheiten.
DK203489A (da) Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
SHIN et al. Molecular cloning and characterization of a gene encoding a 13.1 kDa antigenic protein of Naegleria fowleri
Nicholson et al. BALB/c substrain differences in susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease
NO960858L (no) Anvendelser av myelin - oligodendrocyt-glykoprotein og peptid-deler derav i metoder i forbindelse med autoimmunsykdom
EP0463059B1 (de) Allergene proteine aus ambrosia und verwendung davon
Moore et al. Cerebrospinal meningitis epidemics
Sestak et al. Variability among Cryptosporidium parvum genotype 1 and 2 immunodominant surface glycoproteins
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
Reitan et al. The primary IgM antibody repertoire: a source of potent idiotype immunogens
Araga et al. A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
DE69332956D1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
DE69033974D1 (de) Molekulares klonieren von genomischen und cdna-sequenzen, die für zelluläre rezeptoren für poliovirus kodieren
Holbrook et al. Tolerization as a tool for generating novel monoclonal antibodies
OFFNER et al. Prevention, suppression, and treatment of experimental autoimmune encephalomyelitis with a synthetic T cell receptor V region peptide
Bakela et al. Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A‐induced experimental model
Rumyantsev The origin of individual differences in the course and severity of diseases
Leung Characterization of the pathogenesis of amelanosis in the Smyth line chicken: A model of the human autoimmune disease vitiligo
Purdie et al. Bacterial superantigens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties